|
US6503717B2
(en)
*
|
1999-12-06 |
2003-01-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
|
US7013219B2
(en)
*
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7030215B2
(en)
*
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
|
US20020164634A1
(en)
*
|
2000-08-26 |
2002-11-07 |
Perlegen Sciences, Inc. |
Methods for reducing complexity of nucleic acid samples
|
|
US20020055112A1
(en)
*
|
2000-08-26 |
2002-05-09 |
Nila Patil |
Methods for reducing complexity of nucleic acid samples
|
|
JP2004517638A
(ja)
*
|
2001-02-02 |
2004-06-17 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
機能的核酸の同定方法
|
|
CA2457095A1
(en)
*
|
2001-08-17 |
2003-02-27 |
Toolgen, Inc. |
Zinc finger domain libraries
|
|
CA2469477A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Toolgen, Inc. |
Phenotypic screen of chimeric proteins
|
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
|
AU2003215094B2
(en)
*
|
2002-02-07 |
2008-05-29 |
The Scripps Research Institute |
Zinc finger libraries
|
|
US20030180777A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Victor Bartsevich |
Rapid identification of transcriptional regulatory domains
|
|
US9447434B2
(en)
|
2002-09-05 |
2016-09-20 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
|
AU2003260973A1
(en)
*
|
2002-09-05 |
2004-03-29 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
|
WO2004024084A2
(en)
*
|
2002-09-12 |
2004-03-25 |
Massachusetts Institute Of Technology |
Rb pahtway and chromatin remodeling genes that antagonize let-60 ras signaling
|
|
US20070178454A1
(en)
*
|
2002-10-21 |
2007-08-02 |
Joung J K |
Context sensitive paralell optimization of zinc finger dna binding domains
|
|
AU2003304087A1
(en)
*
|
2002-10-23 |
2004-11-26 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
|
WO2004046387A1
(en)
*
|
2002-11-15 |
2004-06-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
|
KR100766952B1
(ko)
*
|
2002-12-09 |
2007-10-17 |
주식회사 툴젠 |
조절성 징크 핑거 단백질
|
|
US20060183132A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20090124514A1
(en)
*
|
2003-02-26 |
2009-05-14 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
|
US20050100911A1
(en)
*
|
2003-08-06 |
2005-05-12 |
Perlegen Sciences, Inc. |
Methods for enriching populations of nucleic acid samples
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
KR20070060115A
(ko)
|
2004-09-16 |
2007-06-12 |
상가모 바이오사이언스 인코포레이티드 |
단백질 생산을 위한 조성물 및 방법
|
|
KR101363278B1
(ko)
|
2005-06-27 |
2014-02-21 |
엑셀리시스 페이턴트 컴퍼니 엘엘씨 |
이미다졸계 lxr 변조제
|
|
US7718131B2
(en)
*
|
2005-07-06 |
2010-05-18 |
Genetix Limited |
Methods and apparatus for imaging and processing of samples in biological sample containers
|
|
US20070148674A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Wisconsin Alumni Research Foundation (Warf) |
Optical fingerprinting of nucleic acid sequences
|
|
WO2007106603A2
(en)
*
|
2006-01-06 |
2007-09-20 |
The Scripps Research Institute |
Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
|
|
KR100756055B1
(ko)
*
|
2006-01-27 |
2007-09-07 |
연세대학교 산학협력단 |
신생혈관 생성을 조절하는 재조합 아데노바이러스
|
|
WO2007106488A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Wyeth |
Modulators of gluconeogenesis
|
|
WO2007136685A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
|
EP2027262B1
(de)
*
|
2006-05-25 |
2010-03-31 |
Sangamo Biosciences Inc. |
Variante foki-spaltungshälften-domänen
|
|
US7951925B2
(en)
|
2006-05-25 |
2011-05-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
JP2010500029A
(ja)
|
2006-08-11 |
2010-01-07 |
ダウ アグロサイエンシィズ エルエルシー |
ジンクフィンガーヌクレアーゼ媒介相同組換え
|
|
WO2008060510A2
(en)
|
2006-11-13 |
2008-05-22 |
Sangamo Biosciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
AU2008275649B2
(en)
|
2007-07-12 |
2013-09-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
AU2008305590A1
(en)
*
|
2007-09-27 |
2009-04-02 |
Sangamo Therapeutics, Inc. |
Genomic editing in zebrafish using zinc finger nucleases
|
|
ES2585157T3
(es)
*
|
2007-09-27 |
2016-10-04 |
Dow Agrosciences Llc |
Proteínas de dedo de cinc de diseño que se dirigen a los genes de 5-enolpiruvil shikimato-3-fosfato sintasa
|
|
EP2597155B1
(de)
|
2007-10-25 |
2016-11-23 |
Sangamo BioSciences, Inc. |
Verfahren und Zusammensetzungen für gezielte Integration
|
|
WO2009146179A1
(en)
*
|
2008-04-15 |
2009-12-03 |
University Of Iowa Research Foundation |
Zinc finger nuclease for the cftr gene and methods of use thereof
|
|
JP5763530B2
(ja)
|
2008-06-10 |
2015-08-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
Bax−およびBak−欠損細胞株の生成のための方法および組成物
|
|
JP5908725B2
(ja)
|
2008-08-22 |
2016-04-26 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
標的一本鎖開裂および標的組込みのための方法、並びに組成物
|
|
JP5756016B2
(ja)
|
2008-10-29 |
2015-07-29 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
|
|
EP3156494B8
(de)
|
2008-12-04 |
2018-09-19 |
Sangamo Therapeutics, Inc. |
Genomänderung bei ratten mithilfe von zink-finger-nukleasen
|
|
WO2010090744A1
(en)
|
2009-02-04 |
2010-08-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
|
CA2755192C
(en)
*
|
2009-03-20 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
AU2010235161B2
(en)
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
CA2769262C
(en)
*
|
2009-07-28 |
2019-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA2787494C
(en)
|
2010-01-22 |
2019-09-17 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
|
JP6137596B2
(ja)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス, インコーポレイテッド |
遺伝子操作された切断ハーフドメイン
|
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
EP3511420B1
(de)
|
2010-09-27 |
2021-04-07 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur hemmung des eindringens von viren in zellen
|
|
EP2627665B1
(de)
|
2010-10-12 |
2015-12-16 |
The Children's Hospital Of Philadelphia |
Verfahren und Zusammensetzungen zur Behandlung von Hämophilie B
|
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
CA2841710C
(en)
|
2011-07-15 |
2021-03-16 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
CA2841541C
(en)
|
2011-07-25 |
2019-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
EP2758529B1
(de)
|
2011-09-21 |
2019-03-20 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur regulierung der transgenexpression
|
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
WO2013074999A1
(en)
|
2011-11-16 |
2013-05-23 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
|
CA2865011C
(en)
|
2012-02-29 |
2021-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
ES2683071T3
(es)
*
|
2012-04-25 |
2018-09-24 |
Regeneron Pharmaceuticals, Inc. |
Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento
|
|
AU2013256240B2
(en)
*
|
2012-05-02 |
2018-09-20 |
Corteva Agriscience Llc |
Targeted modification of malate dehydrogenase
|
|
CA2871524C
(en)
|
2012-05-07 |
2021-07-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
WO2014011901A2
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
EP2890780B8
(de)
|
2012-08-29 |
2020-08-19 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
|
|
EP4148134A1
(de)
|
2012-09-04 |
2023-03-15 |
The Scripps Research Institute |
Chimäre polypeptide mit gerichteter bindungsspezifität
|
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
|
BR112015004995B1
(pt)
|
2012-09-07 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Método para modificação do genoma de uma célula, uso de uma célula, semente ou planta obtida pelo referido método e nuclease de dedo de zinco sítio específica
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
EP3789405A1
(de)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
|
CA2892448A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
|
EP2954042B1
(de)
|
2013-02-07 |
2017-12-06 |
The General Hospital Corporation |
Tale-transkriptionsaktivatoren
|
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
CN105408483A
(zh)
|
2013-03-15 |
2016-03-16 |
通用医疗公司 |
遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
|
|
US11332719B2
(en)
*
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
DK3456831T3
(da)
|
2013-04-16 |
2021-09-06 |
Regeneron Pharma |
Målrettet modifikation af rottegenom
|
|
US10604771B2
(en)
|
2013-05-10 |
2020-03-31 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP2997146A4
(de)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
EP3058072B1
(de)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
|
US10117899B2
(en)
|
2013-10-17 |
2018-11-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
EP3066110B1
(de)
|
2013-11-04 |
2021-12-29 |
Corteva Agriscience LLC |
Optimale maispflanzen
|
|
JP6633532B2
(ja)
|
2013-11-04 |
2020-01-22 |
ダウ アグロサイエンシィズ エルエルシー |
最適なトウモロコシ遺伝子座
|
|
WO2015066643A1
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal soybean loci
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
MX391904B
(es)
|
2013-11-11 |
2025-03-12 |
Sangamo Biosciences Inc |
Un represor genetico para usarse en el tratamiento de la enfermedad de huntington.
|
|
ES2721936T3
(es)
|
2013-11-13 |
2019-08-06 |
Childrens Medical Center |
Regulación de la expresión genética mediada por las nucleasas
|
|
CA3229275A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
|
MX388127B
(es)
|
2013-12-11 |
2025-03-19 |
Regeneron Pharma |
Metodos y composiciones para la modificacion dirigida de un genoma.
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
PT3102673T
(pt)
|
2014-02-03 |
2020-05-21 |
Sangamo Biosciences Inc |
Métodos e composições para tratamento de beta-talassemia
|
|
EP3110454B1
(de)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur nukleasevermittelten gezielten integration
|
|
EP3929279A1
(de)
|
2014-03-18 |
2021-12-29 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur regulierung der zinkfingerproteinexpression
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
BR112016025849A2
(pt)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
métodos e composições para o tratamento da doença de huntington
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
|
DK3152312T3
(da)
|
2014-06-06 |
2020-04-06 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til modifikation af et mållocus
|
|
AU2015280069B2
(en)
|
2014-06-23 |
2021-08-12 |
The General Hospital Corporation |
Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
|
|
DK3161128T3
(en)
|
2014-06-26 |
2018-11-05 |
Regeneron Pharma |
METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
|
|
EP3169778B1
(de)
|
2014-07-14 |
2023-10-25 |
Washington State University |
Nanos-knock-out zur abladierung von keimbahnzellen
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
EP3845655B1
(de)
|
2014-10-01 |
2025-01-01 |
The General Hospital Corporation |
Verfahren zur erhöhung der effizienz von nucleaseinduzierter homologiegerichteter reparatur
|
|
EP3221457B1
(de)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur gezielten genmodifikation unter verwendung von gepaarten führungs-rns
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
MX388784B
(es)
|
2014-12-19 |
2025-03-20 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
|
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
CA2981077A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
SG10202112057QA
(en)
|
2015-05-12 |
2021-12-30 |
Sangamo Therapeutics Inc |
Nuclease-mediated regulation of gene expression
|
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
HRP20240908T1
(hr)
|
2015-08-06 |
2024-10-25 |
The Curators Of The University Of Missouri |
Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
CA3000816A1
(en)
|
2015-09-11 |
2017-03-16 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
DK3352776T3
(da)
|
2015-09-23 |
2025-06-23 |
Sangamo Therapeutics Inc |
Htt-repressorer og deres anvendelse
|
|
CA3000762A1
(en)
|
2015-09-30 |
2017-04-06 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
US10143760B2
(en)
|
2015-10-28 |
2018-12-04 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
|
EP3380622A4
(de)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zum immunitäts-engineering
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
EP3402533B1
(de)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von neurologischer erkrankung
|
|
JP7012650B2
(ja)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
|
CA3025523A1
(en)
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
|
WO2018013840A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
WO2018039440A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
IL264792B2
(en)
|
2016-08-24 |
2023-10-01 |
Sangamo Therapeutics Inc |
Engineered target-specific zinc-finger nucleases
|
|
JP7256739B2
(ja)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス, インコーポレイテッド |
肝臓遺伝子のモジュレーション
|
|
CA3038690A1
(en)
|
2016-10-05 |
2018-04-12 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
|
EP3525803B1
(de)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immuntherapieverfahren und zusammensetzungen mit tryptophan-stoffwechselweg-modulatoren
|
|
KR102662249B1
(ko)
|
2016-10-14 |
2024-05-03 |
더 제너럴 하스피탈 코포레이션 |
후성적으로 조절되는 부위-특이적 뉴클레아제
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
KR102712926B1
(ko)
|
2016-10-20 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
파브리병의 치료를 위한 방법 및 조성물
|
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
CN110214184B
(zh)
|
2016-12-01 |
2024-07-02 |
桑格摩生物治疗股份有限公司 |
τ蛋白调节剂以及用于其递送的方法和组合物
|
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
EP4276187A3
(de)
|
2016-12-08 |
2024-01-17 |
Case Western Reserve University |
Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
CN117821509A
(zh)
|
2017-04-03 |
2024-04-05 |
编码治疗公司 |
组织选择性转基因表达
|
|
CA3061614A1
(en)
|
2017-04-28 |
2018-11-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
JP2020518245A
(ja)
|
2017-05-03 |
2020-06-25 |
サンガモ セラピューティクス, インコーポレイテッド |
嚢胞性線維症膜貫通コンダクタンス制御因子(cftr)遺伝子の改変のための方法および組成物
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
CA3063733A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Base editors with improved precision and specificity
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
CA3070242A1
(en)
|
2017-07-18 |
2019-01-24 |
Calimmune, Inc. |
Compositions and methods for treating beta-hemoglobinopathies
|
|
EP3658573A1
(de)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Verfahren und zusammensetzungen zur entwicklung von basiseditoren unter verwendung von phagenunterstützter kontinuierlicher entwicklung (pace)
|
|
JP2020530997A
(ja)
|
2017-08-08 |
2020-11-05 |
サンガモ セラピューティクス, インコーポレイテッド |
キメラ抗原受容体媒介性細胞標的化
|
|
EP3676376B1
(de)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
Hocheffiziente baseneditoren mit gam
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
WO2019094725A2
(en)
|
2017-11-09 |
2019-05-16 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
|
CN118345115A
(zh)
|
2017-12-01 |
2024-07-16 |
编码治疗公司 |
工程化的dna结合蛋白
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US12269804B2
(en)
|
2018-01-17 |
2025-04-08 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
|
WO2019143678A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
BR112020014140A2
(pt)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
inibidores de dna-pk
|
|
BR112020015488A2
(pt)
|
2018-02-08 |
2020-12-08 |
Sangamo Therapeutics, Inc. |
Nucleases alvo-específicas modificadas
|
|
CN112585277A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
表达重组受体的t细胞、相关多核苷酸和方法
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
JP7332622B2
(ja)
|
2018-04-18 |
2023-08-23 |
サンガモ セラピューティクス, インコーポレイテッド |
ハンチンチン(htt)の調節のためのジンクフィンガータンパク質組成物
|
|
KR102853088B1
(ko)
|
2018-05-11 |
2025-09-02 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3820495A4
(de)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
|
|
KR102894715B1
(ko)
|
2018-08-03 |
2025-12-03 |
빔 테라퓨틱스, 인크. |
핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
|
|
JP7541508B2
(ja)
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
EP4234570A3
(de)
|
2018-09-18 |
2023-12-13 |
Sangamo Therapeutics, Inc. |
Für programmierten zelltod 1 (pd1) spezifische nukleasen
|
|
EP3852911B1
(de)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
|
|
IL326834A
(en)
|
2018-10-02 |
2026-04-01 |
Sangamo Therapeutics Inc |
Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
|
KR20210094609A
(ko)
|
2018-11-28 |
2021-07-29 |
포티 세븐, 인코포레이티드 |
절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
|
|
KR20210104835A
(ko)
|
2018-12-19 |
2021-08-25 |
누클레인, 엘엘씨 |
분자 진단을 위한 장치 및 방법
|
|
CN113423419A
(zh)
|
2019-01-04 |
2021-09-21 |
桑格摩生物治疗股份有限公司 |
用于治疗法布里病的方法和组合物
|
|
WO2020146250A1
(en)
|
2019-01-07 |
2020-07-16 |
Dana-Farber Cancer Institute, Inc. |
SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
|
|
PL3908568T3
(pl)
|
2019-01-11 |
2024-12-02 |
Acuitas Therapeutics, Inc. |
Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
|
US11866469B2
(en)
|
2019-02-06 |
2024-01-09 |
Klogenix Llc |
DNA binding proteins and uses thereof
|
|
CA3106693A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
WO2020205838A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Methods for the treatment of beta-thalassemia
|
|
CA3136119A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP7618581B2
(ja)
|
2019-04-23 |
2025-01-21 |
サンガモ セラピューティクス, インコーポレイテッド |
9番染色体オープンリーディングフレーム72遺伝子発現のモジュレーターおよびその使用
|
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
SG11202113048SA
(en)
|
2019-05-29 |
2021-12-30 |
Encoded Therapeutics Inc |
Compositions and methods for selective gene regulation
|
|
AU2020322021A1
(en)
|
2019-07-30 |
2022-02-10 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
EP4007596A1
(de)
|
2019-08-01 |
2022-06-08 |
Sana Biotechnology, Inc. |
Dux4+-exprimierende zellen und ihre verwendungen
|
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー,インコーポレイテッド |
Cd24発現細胞およびそれらの用途
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
DK3812472T3
(da)
|
2019-10-21 |
2023-02-20 |
Univ Freiburg Albert Ludwigs |
Virkelig uvildig in vitro-undersøgelse til profilering af off-target-aktivitet af en eller flere målspecifikke programmerbare nukleaser i celler (abnoba-seq)
|
|
WO2021087366A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
|
TW202132565A
(zh)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Gin重組酶變異體
|
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
|
US20230235309A1
(en)
|
2020-02-05 |
2023-07-27 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
|
BR112022017715A2
(pt)
|
2020-03-04 |
2022-11-16 |
Flagship Pioneering Innovations Vi Llc |
Métodos e composições para modular um genoma
|
|
CN115916974A
(zh)
|
2020-03-05 |
2023-04-04 |
加利福尼亚大学董事会 |
用于产生具有最小化的生物质副产物的植物的方法及其相关的植物
|
|
WO2021183353A1
(en)
|
2020-03-09 |
2021-09-16 |
Nuclein, Llc |
Apparatus and methods for molecular diagnostics
|
|
EP4125961A1
(de)
|
2020-03-25 |
2023-02-08 |
Sana Biotechnology, Inc. |
Hypoimmunogene nervenzellen zur behandlung von neurologischen erkrankungen und zuständen
|
|
US11091524B1
(en)
|
2020-04-22 |
2021-08-17 |
Houston Gene Therapeutics Llc |
Compositions for treatment of vascular disease
|
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
|
JP7891314B2
(ja)
|
2020-05-06 |
2026-07-16 |
セレクティス ソシエテ アノニム |
治療用タンパク質の送達のために細胞を遺伝子改変する方法
|
|
WO2021224395A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
CN111549061A
(zh)
*
|
2020-05-07 |
2020-08-18 |
西南大学 |
一种高通量筛选真核生物细胞响应环境极端pH的靶点基因的方法
|
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
EP4171616A1
(de)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Manipulierte t-zellen zur bedingten expression eines rekombinanten rezeptors, zugehörige polynukleotide und verfahren
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
AU2021325941A1
(en)
|
2020-08-13 |
2023-03-09 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
EP4501951A3
(de)
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
US20240000051A1
(en)
|
2020-11-16 |
2024-01-04 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
US11965022B2
(en)
|
2020-12-31 |
2024-04-23 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating CAR-T activity
|
|
WO2022155500A1
(en)
|
2021-01-14 |
2022-07-21 |
Senti Biosciences, Inc. |
Secretable payload regulation
|
|
JP2024507533A
(ja)
|
2021-02-19 |
2024-02-20 |
ビーム・セラピューティクス・インコーポレイテッド |
遺伝子治療のための組み換え狂犬病ウイルス
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
EP4326852A4
(de)
|
2021-04-22 |
2025-04-23 |
Artec Biotech, Inc. |
Verfahren zur herstellung hämatopoietischer zellen aus stammzellen unter verwendung vaskulärer organoide
|
|
AU2022273536A1
(en)
|
2021-05-14 |
2023-11-16 |
Becton, Dickinson And Company |
Multiplexed unbiased nucleic acid amplification method
|
|
AU2022272723A1
(en)
|
2021-05-14 |
2023-11-30 |
Becton, Dickinson And Company |
Methods for making libraries for nucleic acid sequencing
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
CA3225283A1
(en)
|
2021-07-14 |
2023-01-19 |
Sonja SCHREPFER |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
US20260053851A1
(en)
|
2021-08-11 |
2026-02-26 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
WO2023035011A1
(en)
|
2021-09-03 |
2023-03-09 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
CN118369429A
(zh)
|
2021-09-08 |
2024-07-19 |
比姆医疗股份有限公司 |
病毒引导rna递送
|
|
KR20260037664A
(ko)
|
2021-09-08 |
2026-03-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
게놈을 조절하기 위한 방법 및 조성물
|
|
US20250313861A1
(en)
|
2021-10-22 |
2025-10-09 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
US20250043269A1
(en)
|
2021-11-03 |
2025-02-06 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad |
Precise Genome Editing Using Retrons
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
US20250064032A1
(en)
|
2021-12-10 |
2025-02-27 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4479084A1
(de)
|
2022-02-14 |
2024-12-25 |
Sana Biotechnology, Inc. |
Verfahren zur behandlung von patienten mit einer vorherigen fehlgeschlagenen therapie mit hypoimmunogenen zellen
|
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
US20250320521A1
(en)
|
2022-05-09 |
2025-10-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
US20250302994A1
(en)
|
2022-05-09 |
2025-10-02 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
AU2023325079A1
(en)
|
2022-08-16 |
2025-02-13 |
President And Fellows Of Harvard College |
Evolved cytosine deaminases and methods of editing dna using same
|
|
AU2023329392A1
(en)
|
2022-08-25 |
2025-02-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024155745A1
(en)
|
2023-01-18 |
2024-07-25 |
The Broad Institute, Inc. |
Base editing-mediated readthrough of premature termination codons (bert)
|
|
US20260232729A1
(en)
|
2023-02-03 |
2026-08-13 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024187174A2
(en)
|
2023-03-09 |
2024-09-12 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
CN121843705A
(zh)
|
2023-05-03 |
2026-04-10 |
萨那生物科技公司 |
工程化胰岛细胞的给药和施用方法
|
|
JP2026518711A
(ja)
|
2023-05-16 |
2026-06-09 |
フラッグシップ ラブズ 114, インコーポレイテッド |
標的遺伝子のメチル化を調節するための方法及び組成物
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
TW202515898A
(zh)
|
2023-06-30 |
2025-04-16 |
日商武田藥品工業股份有限公司 |
Htt抑制物及其用途
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
EP4771154A2
(de)
|
2023-09-01 |
2026-07-08 |
Renagade Therapeutics Management Inc. |
Geneditierungssysteme, zusammensetzungen und verfahren zur behandlung des vexas-syndroms
|
|
WO2025064469A1
(en)
|
2023-09-18 |
2025-03-27 |
Omega Therapeutics, Inc. |
Methods for assessing dosage for epigenetic modifying agents
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025193628A2
(en)
|
2024-03-09 |
2025-09-18 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2026072421A2
(en)
|
2024-09-27 |
2026-04-02 |
The Broad Institute, Inc. |
Base editing methods and compositions for editing prnp in the treatment of prion disease
|
|
WO2026083329A1
(en)
|
2024-10-18 |
2026-04-23 |
Precision Biosciences, Inc. |
Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
|
|
WO2026083328A1
(en)
|
2024-10-18 |
2026-04-23 |
Precision Biosciences, Inc. |
Base editing nucleotide sequences using homology directed repair
|
|
WO2026123001A2
(en)
|
2024-12-06 |
2026-06-11 |
Umoja Biopharma, Inc. |
Lineage-loci engineered cell therapy and related methods of producing and using same
|
|
WO2026136848A2
(en)
|
2024-12-20 |
2026-06-25 |
Juno Therapeutics, Inc. |
Cd70-targeted cars and engineered cells comprising same and related methods
|